Clinical Trials Logo

Filter by:
NCT ID: NCT04506450 Completed - Hip Arthroplasty Clinical Trials

Peripheral Nerve Block vs Spinal Anesthesia in Hip Surgery

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Anesthesia plays an important role in the patient's outcome: each anesthesiological technique has a different cardiovascular impact, because they act differently on the autonomic nervous system, which in turn regulates heart rate, myocardial contractility and vascular tone. Subarachnoid anesthesia can result in a reduction in cardiac output, hypotension and bradycardia due to blockage of the nerve fibers of the sympathetic system, while peripheral nerve block is associated with a lower impact on the autonomic nervous system, therefore less influence on hemodynamic changes compared to subarachnoid anesthesia. Hypotension can lead to myocardial ischaemia, especially in patients at high surgical risk. In addition, peripheral nerve block allows for better coverage from postoperative pain compared to subarachnoid anesthesia in patients undergoing hip surgery. This leads to less postoperative stress, with less impact on cardiac and respiratory function. Numerous studies have shown the efficacy and safety of regional anesthesia in hip surgery. This study aims to compare the hemodynamic changes of subarachnoid anesthesia and peripheral nerve block in patients who underwent total and partial hip replacement

NCT ID: NCT04506385 Completed - Metabolomic Profile Clinical Trials

Metabolomic Effects of Probiotics Administration

MAPPINg
Start date: April 20, 2020
Phase: N/A
Study type: Interventional

Background: The establishment of the beneficial interactions between the host and its microbiota is essential for the development and correct functioning of the organism, since microflora alterations can lead to many chronic degenerative diseases. In this context, probiotics are used to improve balanced microbial communities and therefore exert substantial health-promoting effects to the host. Objective: The aim of the present study is to monitor the molecular outcomes, obtained by gut microflora modulation through probiotic treatment, on human urine and serum metabolic profiles, with a 1H-Nuclear Magnetic Resonance -based metabolomic approach.

NCT ID: NCT04506320 Completed - Multiple Myeloma Clinical Trials

Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma

NEW_ALL_MM
Start date: December 17, 2021
Phase:
Study type: Observational

This is a retrospective observational study of epidemiological surveillance, multicenter, non-profit, spontaneous, Italian on patients submitted to allo-HSCT among Italian Transplant Centers GITMO. This study will evaluate all consecutive adult patients who received novel drugs after hematopoietic stem cell transplantation from related and unrelated donors between January 1, 2009 to December 31, 2018 in GITMO-affiliated Centers. This study will evaluate approximately 300 subjects (with competitive enrolment) from GITMO investigational centers.

NCT ID: NCT04505774 Active, not recruiting - Covid19 Clinical Trials

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

ACTIV-4A
Start date: September 4, 2020
Phase: Phase 4
Study type: Interventional

This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients

NCT ID: NCT04504825 Active, not recruiting - AL Amyloidosis Clinical Trials

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

Start date: February 2, 2021
Phase: Phase 3
Study type: Interventional

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival and it is safe and well tolerated in patients with stage IIIb AL amyloidosis.

NCT ID: NCT04504591 Terminated - Brugada Syndrome 1S Clinical Trials

Validation Of A New S-ICD Algorithm To Reduce Oversensing Of Dynamic T-Waves In Patients With Brugada Syndrome

DE-08-16
Start date: December 14, 2017
Phase:
Study type: Observational

The main objective of this study will be to assess the efficacy of S-ICD with SMART Pass to discriminate dynamic T-waves amplitudes and morphologies over time. Pilot, multi-centric, prospective, blinded, one arm (repeated measures), non-interventional study. Objective is to setup a 8-center data collection registry between Switzerland, Italy and Belgium.

NCT ID: NCT04504552 Recruiting - Clinical trials for Oral Premalignant Lesions

Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions

IMPEDE
Start date: July 16, 2020
Phase: Phase 2
Study type: Interventional

This trial is designed as a prospective, multi-centre, open-label, single-arm, phase II study. Oral Premalignant Lesions (OPL) may be considered the equilibrium phase of the immunoediting concept, i.e. a dynamic process between the tumour cells and the immune system including surveillance by the immune system or tumour progression. Thus, an imbalance in immunosuppressive microenvironment is a possible key in malignant transformation. In this regard, the activation of the PD-1/PD-L1 pathway has a central role, witnessed by the expression of PD-L1 by multiple cell types within the microenvironment of OPL (tumour-associated macrophages, fibroblasts, lymphocytes) and by the fact that PD-L1 expression in epithelial and subepithelial cells is associated with malignant transformation. The use of checkpoint inhibitors in this setting seems to be justified by this rationale. Employing intermediate end-point markers during preventive strategies against OPL may allow the conduction of smaller trials, able to give insights for designing larger studies and to better select the population receiving benefit from the treatment. In this regard, the evaluation of phenotypic changes (reduction in size or in grade of dysplasia) may not be enough to assess the potential benefit of an intervention. Modulation of molecular markers may be more precise indicator of oral cancer risk in patients with OPL. Thus, the change in LOH at critical loci may be considered intermediate end-point biomarkers of prevention as well as predictors of cancer risk at baseline. Previous experience with anti-EGFR agents showed the feasibility of such measures in a prevention trial.

NCT ID: NCT04504383 Completed - Clinical trials for Ulcerative Colitis Chronic Moderate

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Start date: August 5, 2020
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability, and clinical efficacy of PN-943 450 mg twice daily [BID] and PN-943 150 mg BID, compared with placebo BID, in subjects with moderate to severe active Ulcerative Colitis (UC).

NCT ID: NCT04503395 Recruiting - Clinical trials for Aortic Aneurysm, Abdominal

ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

SOCRATES
Start date: May 21, 2021
Phase: N/A
Study type: Interventional

The aim of this randomized study is to compare the safety and performance of EndoVascular Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).

NCT ID: NCT04503135 Completed - Intensive Care Unit Clinical Trials

Catheter Associated Asymptomatic Thrombosis in Intensive Care Unit

CAAT
Start date: September 1, 2020
Phase:
Study type: Observational

This study aims to describe the incidence of catheter-related and non-catheter-related thrombosis in a population of adults in ICU and to assess its correlation with alteration of coagulation parameters.